The FirstTake Podcast – FirstWord’s editors discuss the controversial approval of Biogen’s Aduhelm

Ref: ViewPoints Desk

FirstWord Pharma PLUS editors Becky Simon, Michael Flanagan and Simon King discuss FDA approval of the first potentially disease modifying Alzheimer’s disease treatment Aduhelm (aducanumab), which has dominated industry headlines this week.

Simon also speaks to EQRx President and Chief Operating Office Melanie Nallicheri about the company’s aspirations to disrupt pharmaceutical pricing and what describes as its “data coming out part” at ASCO this past weekend.

Listen on apple podcasts, Spotify or Google